Yves Levy

Publications | Mémoires et thèses

La recherche avancée est accessible via Serval

Les publications peuvent être gérées en accédant à Serval via MyUnil


7 publications

2023 | 2022 | 2021 | 2020 | 2019 |
2023
 
Broadly potent anti-SARS-CoV-2 antibody shares 93% of epitope with ACE2 and provides full protection in monkeys.
Fenwick C., Turelli P., Duhoo Y., Lau K., Herate C., Marlin R., Lamrayah M., Campos J., Esteves-Leuenberger L., Farina A. et al., 2023/12. The Journal of infection, 87 (6) pp. 524-537. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_0A69FF2015C1]
2022
 
Patient-derived monoclonal antibody neutralizes SARS-CoV-2 Omicron variants and confers full protection in monkeys.
Fenwick C., Turelli P., Ni D., Perez L., Lau K., Herate C., Marlin R., Lana E., Pellaton C., Raclot C. et al., 2022/09. Nature microbiology, 7 (9) pp. 1376-1389. Peer-reviewed.
[DOI][WoS][Pmid][serval:BIB_539E1A543541]
2021
A highly potent antibody effective against SARS-CoV-2 variants of concern.
Fenwick C., Turelli P., Perez L., Pellaton C., Esteves-Leuenberger L., Farina A., Campos J., Lana E., Fiscalini F., Raclot C. et al., 2021/10/12. Cell reports, 37 (2) p. 109814. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6CC56B59453A]
CD177, a specific marker of neutrophil activation, is associated with coronavirus disease 2019 severity and death.
Lévy Y., Wiedemann A., Hejblum B.P., Durand M., Lefebvre C., Surénaud M., Lacabaratz C., Perreau M., Foucat E., Déchenaud M. et al., 2021/07/23. iScience, 24 (7) p. 102711. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_909F730EC11C]
A Randomized Placebo-Controlled Efficacy Study of a Prime Boost Therapeutic Vaccination Strategy in HIV-1-Infected Individuals: VRI02 ANRS 149 LIGHT Phase II Trial.
Lévy Y., Lacabaratz C., Lhomme E., Wiedemann A., Bauduin C., Fenwick C., Foucat E., Surenaud M., Guillaumat L., Boilet V. et al., 2021/04/12. Journal of virology, 95 (9) pp. e02165-20. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_6673B3848E48]
2020
TLR-9 agonist and CD40-targeting vaccination induces HIV-1 envelope-specific B cells with a diversified immunoglobulin repertoire in humanized mice.
Godot V., Tcherakian C., Gil L., Cervera-Marzal I., Li G., Cheng L., Ortonne N., Lelièvre J.D., Pantaleo G., Fenwick C. et al., 2020/11. PLoS pathogens, 16 (11) pp. e1009025. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_772249C57318]
2019
Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses.
Perdiguero B., Gómez C.E., García-Arriaza J., Sánchez-Corzo C., Sorzano CÓS, Wilmschen S., von Laer D., Asbach B., Schmalzl C., Peterhoff D. et al., 2019. Frontiers in immunology, 10 p. 2941. Peer-reviewed.
[URN][DOI][WoS][Pmid][serval:BIB_61B1B7E651FD]
Partagez:
Unicentre - CH-1015 Lausanne
Suisse
Tél. +41 21 692 11 11
Canton de Vaud
Swiss University